Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced December 2014 through January 2015.
Personalized CNS medicine company Assurex raises $30mm in Series D round
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
